Cargando…

Juvenile idiopathic arthritis treated with biological therapies

Detalles Bibliográficos
Autores principales:	Velloso Feijoo, Maria Luisa, Perez, Rosalia Martinez, Montañes, Julia Uceda, Marenco de la Fuente, Jose Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508835/ http://dx.doi.org/10.1186/1479-5876-10-S3-P46

Ejemplares similares

Seronegative and seropositive rheumatoid arthritis treated with rituximab
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012)

Analysis of biologic therapy in rheumatoid arthritis in a southern Spanish hospital population
por: Uceda-Montañés, J, et al.
Publicado: (2010)

Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalia, et al.
Publicado: (2011)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2012)

Changes in nailfold videocapillaroscopy in patients with granulomatosis with polyangiitis (Wegener’s): an observational study
por: Uceda, Julia, et al.
Publicado: (2012)

Wegener granulomatosis: type of presentation and initial treatment in a series of 23 cases
por: Martínez-Pérez, Rosalia, et al.
Publicado: (2012)

Impact of biologics on growth in children with juvenile idiopathic arthritis
por: Uettwiller, F, et al.
Publicado: (2011)

Renal disorder and biological treatment in juvenile idiopathic arthritis
por: Mateescu, Lidia, et al.
Publicado: (2014)

Switching to an alternative biological agent in juvenile idiopathic arthritis (I)
por: Remesal, A, et al.
Publicado: (2011)

Switching to an alternative biological agent in juvenile idiopathic arthritis (II)
por: Murias, S, et al.
Publicado: (2011)

Eight years of experience with biological treatment in juvenile idiopathic arthritis
por: Mourão, A F, et al.
Publicado: (2010)

Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
por: Bracaglia, C, et al.
Publicado: (2008)

Phenotypes of juvenile idiopathic arthritis
por: Rokhlina, Faina, et al.
Publicado: (2014)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Efficacy of abatacept in juvenile idiopathic arthritis related uveitis
por: Katargina, LA, et al.
Publicado: (2011)

Juvenile idiopathic arthritis: the transition to adulthood
por: Fernandes, Susana, et al.
Publicado: (2014)

Ten years of experience of biologics in juvenile idiopathic arthritis: focus for the reasons of withdrawals
por: Arsenyeva, Svetlana V, et al.
Publicado: (2014)

Multicenter retrospective study of biological tolerance in juvenile idiopathic arthritis (jir-cohort)
por: Cabrera, Natalia, et al.
Publicado: (2014)

The reason to stop infliximab is clearly related to the existence of new alternatives: a correspondence analysis of biologics, reasons to stop, and time periods
por: Uceda, Julia, et al.
Publicado: (2012)

Varicella immunity and vaccine response in children with juvenile idiopathic arthritis treated with DMARD
por: Boldingh, AM, et al.
Publicado: (2011)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

PReS-FINAL-2146: Trends in prescription of biologics and outcomes of juvenile idiopathic arthritis; results of the Dutch national arthritis and biologicals in children register
por: Otten, MH, et al.
Publicado: (2013)

Clinical and articular presentation of juvenile idiopathic arthritis
por: Ravichandran, R, et al.
Publicado: (2008)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

Depression, anxiety and pain in juvenile idiopathic arthritis
por: Erdogdu, D, et al.
Publicado: (2008)

Illness representation in adolescents with juvenile idiopathic arthritis
por: Lelieveld, OTHM, et al.
Publicado: (2008)

Systemic juvenile idiopathic arthritis in the republic of Bashkortostan
por: Malievskiy, VA
Publicado: (2011)

Familial hypercholesterolemia misinterpreted as juvenile idiopathic arthritis
por: Schou, AJ, et al.
Publicado: (2011)

TH17-phenotypes of juvenile idiopathic arthritis
por: Turtsevich, Inga Z, et al.
Publicado: (2014)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Juvenile idiopathic arthritis is a diagnosis of exclusion
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

PReS-FINAL-2052: Costs of biologics in juvenile idiopathic arthritis: past, present and future
por: Prince, FH, et al.
Publicado: (2013)

Long term functional outcome and quality of life of patients with refractory juvenile idiopathic arthritis treated with etanercept: results of the dutch arthritis and biologicals in children register
por: Anink, Janneke, et al.
Publicado: (2014)

Ankle arthritis predicts worse outcome in children with juvenile idiopathic arthritis
por: Esbjörnsson, Anna-Clara, et al.
Publicado: (2014)

PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis
por: Woerner, A, et al.
Publicado: (2013)

Macrophage activation syndrome during treatment with biological therapy in patients with systemic juvenile idiopathic arthritis
por: Boteanu, Alina Lucica, et al.
Publicado: (2014)

PReS-FINAL-2111: Cytomegalovirus, Epstein Barr virus and Varicella-Zoster virus infections in children with juvenile idiopathic arthritis treated with biologics
por: Remy Piccolo, V, et al.
Publicado: (2013)

PReS-FINAL-2033: Increase of adverse mild and moderate adverse events among patients with juvenile idiopathic arthritis treated with biological therapies
por: Guillen Astete, CA, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_u4b69g2ceru9qgr10co1c8rrb3